MedTrace Logo

Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)

NCT02959905 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2023-02-02

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety of TSA-CTL in the treatment of advanced solid tumors.

The secondary objective of this study is to evaluate preliminarily the effect of TSA-CTL in the treatment of advanced solid tumors.

Conditions

  • Solid Cancer

Interventions

BIOLOGICAL

TSA-CTL

Patients will receive TSA-CTL iv over 20-30 minutes on day 0.

DRUG

Cyclophosphamide

Cyclophosphamide 500 mg/m2/day iv on day -5 for one day.

DRUG

Fludarabine

Fludarabine 25 mg/m2/day iv over 30 minutes on day -5 and -4 for two days.

DRUG

Cyclophosphamide

Cyclophosphamide 500 mg/m2/day iv on day -5 and -4 for two days.

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • BGI, China

    lead OTHER

Principal Investigators

  • Xiao Sh Zhang, Doctor · Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-22
Primary Completion
2020-09-01
Completion
2022-05-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02959905 on ClinicalTrials.gov